Jim Wells (UCSF)

An­ti­bod­ies once act­ed on­ly as pro­tein block­ers. Now, sci­en­tists are find­ing new ways to make them pro­tein de­stroy­ers

The first lab-made an­ti­body med­i­cine was ap­proved in 1986 — it bound to an anti­gen known as CD3 on T cells and was meant to pre­vent kid­ney trans­plant re­jec­tion. While an­ti­body tech­nol­o­gy im­proved, most an­ti­bod­ies were made as block­ing agents, neu­ter­ing clamps that at­tacked cells and pro­teins.

But then sci­en­tists got cre­ative with their en­gi­neer­ing. They made an­ti­body-drug con­ju­gates, or AD­Cs for short, which at­tached tox­ins or drugs to the an­ti­bod­ies, en­abling them to kill cells. Then they made CAR-T ther­a­pies, which at­tached a pa­tient’s T cell to the tar­get­ing frag­ment of an an­ti­body, to de­stroy can­cer cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA